Adadagrasib provides antitumor activity against KRAS G12C mutant metastatic colorectal cancer, both as monotherapy and in combination with cetuximab | Medicine in 2 Minutes
1. Overall tumor response to adagrasib monotherapy treatment was 23% 46% in combination with cetuximab. 2. Median progression-free survival was 5.6 months on adagrasib monotherapy and 6.9 months on combination therapy with cetuximab. Level of evidence assessment: 2 (Good) Summary of the study: Rat sarcoma virus oncogene homolog Kirsten (KRAS) is responsible for oncogenesis in …